BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30679388)

  • 1. First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
    Shimomura A; Yamamoto N; Kondo S; Fujiwara Y; Suzuki S; Yanagitani N; Horiike A; Kitazono S; Ohyanagi F; Doi T; Kuboki Y; Kawazoe A; Shitara K; Ohno I; Banerji U; Sundar R; Ohkubo S; Calleja EM; Nishio M
    Mol Cancer Ther; 2019 Mar; 18(3):531-540. PubMed ID: 30679388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
    Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
    Shapiro GI; Kwak E; Dezube BJ; Yule M; Ayrton J; Lyons J; Mahadevan D
    Clin Cancer Res; 2015 Jan; 21(1):87-97. PubMed ID: 25336693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
    Infante JR; Weiss GJ; Jones S; Tibes R; Bauer TM; Bendell JC; Hinson JM; Von Hoff DD; Burris HA; Orlemans EO; Ramanathan RK
    Eur J Cancer; 2014 Nov; 50(17):2897-904. PubMed ID: 25262379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
    Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
    Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.
    Ohkubo S; Kodama Y; Muraoka H; Hitotsumachi H; Yoshimura C; Kitade M; Hashimoto A; Ito K; Gomori A; Takahashi K; Shibata Y; Kanoh A; Yonekura K
    Mol Cancer Ther; 2015 Jan; 14(1):14-22. PubMed ID: 25416789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
    Wagner AJ; Chugh R; Rosen LS; Morgan JA; George S; Gordon M; Dunbar J; Normant E; Grayzel D; Demetri GD
    Clin Cancer Res; 2013 Nov; 19(21):6020-9. PubMed ID: 24045182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.
    Doi T; Takahashi S; Aoki D; Yonemori K; Hara H; Hasegawa K; Takehara K; Harano K; Yunokawa M; Nomura H; Shimoi T; Horie K; Ogasawara A; Okame S
    Cancer Chemother Pharmacol; 2024 Jun; 93(6):605-616. PubMed ID: 38411735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors.
    Doi T; Matsubara N; Kawai A; Naka N; Takahashi S; Uemura H; Yamamoto N
    Invest New Drugs; 2020 Aug; 38(4):1175-1185. PubMed ID: 31820255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.
    Do K; Speranza G; Chang LC; Polley EC; Bishop R; Zhu W; Trepel JB; Lee S; Lee MJ; Kinders RJ; Phillips L; Collins J; Lyons J; Jeong W; Antony R; Chen AP; Neckers L; Doroshow JH; Kummar S
    Invest New Drugs; 2015 Aug; 33(4):921-30. PubMed ID: 26082332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
    Do KT; O'Sullivan Coyne G; Hays JL; Supko JG; Liu SV; Beebe K; Neckers L; Trepel JB; Lee MJ; Smyth T; Gannon C; Hedglin J; Muzikansky A; Campos S; Lyons J; Ivy P; Doroshow JH; Chen AP; Shapiro GI
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):815-827. PubMed ID: 33095286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
    Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
    Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.
    Saito Y; Takahashi T; Obata Y; Nishida T; Ohkubo S; Nakagawa F; Serada S; Fujimoto M; Ohkawara T; Nishigaki T; Sugase T; Koh M; Ishida T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Yamasaki M; Hirota S; Naka T; Mori M; Doki Y
    Br J Cancer; 2020 Mar; 122(5):658-667. PubMed ID: 31857719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
    Kawazoe A; Itahashi K; Yamamoto N; Kotani D; Kuboki Y; Taniguchi H; Harano K; Naito Y; Suzuki M; Fukutani M; Higuchi T; Ikeno T; Wakabayashi M; Sato A; Koyama S; Nishikawa H; Shitara K
    Clin Cancer Res; 2021 Dec; 27(24):6709-6715. PubMed ID: 34593531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
    Jänne PA; Boss DS; Camidge DR; Britten CD; Engelman JA; Garon EB; Guo F; Wong S; Liang J; Letrent S; Millham R; Taylor I; Eckhardt SG; Schellens JH
    Clin Cancer Res; 2011 Mar; 17(5):1131-9. PubMed ID: 21220471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
    Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F
    Eur J Cancer; 2017 Dec; 87():131-139. PubMed ID: 29145039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
    Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Fujiwara Y; Tamura Y; Wakui H; Honda K; Mizugaki H; Kitazono S; Tanabe Y; Asahina H; Yamazaki N; Suzuki S; Matsuoka M; Ogita Y; Tamura T
    Invest New Drugs; 2015 Jun; 33(3):641-51. PubMed ID: 25809858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study.
    Schöffski P; Besse B; Gauler T; de Jonge MJ; Scambia G; Santoro A; Davite C; Jannuzzo MG; Petroccione A; Delord JP
    Ann Oncol; 2015 Mar; 26(3):598-607. PubMed ID: 25488684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
    Rajan A; Kelly RJ; Trepel JB; Kim YS; Alarcon SV; Kummar S; Gutierrez M; Crandon S; Zein WM; Jain L; Mannargudi B; Figg WD; Houk BE; Shnaidman M; Brega N; Giaccone G
    Clin Cancer Res; 2011 Nov; 17(21):6831-9. PubMed ID: 21908572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.